Ivermectin Safety in Small Children (ISSC)

• ClinicalTrials.gov Identifier: NCT04332068
• Recruitment Status: Not yet recruiting
• First Posted: April 2, 2020
• Last Update Posted: June 22, 2022
• Sponsor: University of Oxford
• Collaborators: Chittagong Medical College; Fundação Alfredo da Matta (FUAM); Kenya Medical Research Institute; Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD); Medical Research Center Unit The Gambia (MRCG)
• Information provided by (Responsible Party): University of Oxford

Study Description

Brief Summary:

This trial will evaluate the safety, pharmacokinetics, and efficacy of ivermectin in scabies infected children weighing 5 to less than 15kg. This will allow future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15kg to treat numerous NTDs, allowing this young age group equitable access to the numerous benefits of ivermectin therapy.

Condition or disease	Intervention/treatment	Phase
Scabies	Drug: Oral ivermectin; Drug: Permethrin Cream; Other: Placebo tablet; Other: Placebo cream	Phase 2

Detailed Description:

Scabies is a skin infestation caused by a mite called Sarcoptes scabiei. Scabies is characterised by a rash and severe itching, which is an allergic reaction to the eggs and feces the females deposit as they tunnel under the skin. Oral ivermectin is a very safe and beneficial drug which has been shown to be highly effective for the treatment of scabies and more than a dozen different neglected tropical diseases (NTDs), many of which are associated with important public health problems. Current label indications for ivermectin prevent use in small children weighing less than 15 kg, due to limited safety data in this group. Many of the NTD treatment options for small children rely on compounds that are less safe and/or efficacious compared to oral ivermectin. Our proposal will establish the safety and pharmacokinetics of escalating doses of ivermectin (200, 400, 800 µg/kg) to treat scabies infected children weighing 5 to less than 15 kg. The safety assessment will provide crucial evidence on the use of ivermectin for numerous diseases in children weighing 5 to less than 15 kg. The information from measuring drug concentrations in the patients will inform the optimal dosing of this drug in small children. Assessment of the efficacy of ivermectin, compared to permethrin cream, for the treatment of scabies in small children can provide an important alternative treatment for this widespread disease. This trial has been funded by the Wellcome Trust (grant reference number: 218524/Z/19/Z).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 398 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment

Intervention Model Description

The trial will initially randomize 30 participants at each site to receive control (permethrin cream), ivermectin 200 and 400 µg/kg (10:10:10) and review this data before escalation to ivermectin 800 µg/kg. Once the initial 30 participants have been treated a DSMB consultation will be performed for each site. If deemed safe to escalate to ivermectin 800 µg/kg, then remaining participants at each site will be treated with control (permethrin cream), ivermectin 200, 400, and 800 µg/kg (15: 15: 15: 25).

The Bangladesh and Brazil sites will initially randomize 30 participants receive control (permethrin cream) and ivermectin 200 µg/kg (15:15) and review this data before escalation to ivermectin 400 µg/kg. Once the initial 30 participants have been treated a DSMB consultation will be performed. If deemed safe to escalate to ivermectin 400 µg/kg, then remaining participants at the Bangladesh site will be treated with control (permethrin cream), ivermectin 200, 400 µg/kg (18: 18: 33).

• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: This is a double-blind trial so the participants, their parents, guardians or carers, administering clinicians, attending nurses, the central research team, and independent outcome assessors will all be blinded.
• Primary Purpose: Treatment
• Official Title: A Randomised, Double-blind, Placebo-controlled Trial to Assess the Safety, Pharmacokinetics, and Efficacy of Escalating Doses of Oral Ivermectin in Scabies Infected Children Weighing 5 to Less Than 15 Kilograms
• Estimated Study Start Date: November 1, 2022
• Estimated Primary Completion Date: March 31, 2023
• Estimated Study Completion Date: December 31, 2023

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Arm 1; Permethrin cream plus placebo tablets	Drug: Permethrin Cream; permethrin cream 5% (Pioletal® Plus) is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender.; Other Name: Pioletal® Plus; Other: Placebo tablet; placebo tablets are round, white, scored on one side. There are no active substances in the placebo tablets.
Experimental: Arm 2; Ivermectin (200 µg/kg) plus placebo cream	Drug: Oral ivermectin; Ivermectin (Iver P®) 3 mg tablets are round, white, and scored on one side. Ivermentin 3mg tablets will be crushed and mixed thoroughly in 10mL of water.; Other Name: Iver P®; Other: Placebo cream; A placebo cream is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender but lacking the permethrin agent.
Experimental: Arm 3; Ivermectin (400 µg/kg) plus placebo cream	Drug: Oral ivermectin; Ivermectin (Iver P®) 3 mg tablets are round, white, and scored on one side. Ivermentin 3mg tablets will be crushed and mixed thoroughly in 10mL of water.; Other Name: Iver P®; Other: Placebo cream; A placebo cream is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender but lacking the permethrin agent.
Experimental: Arm 4; Ivermectin (800 µg/kg) plus placebo cream (except the Bangladesh site)	Drug: Oral ivermectin; Ivermectin (Iver P®) 3 mg tablets are round, white, and scored on one side. Ivermentin 3mg tablets will be crushed and mixed thoroughly in 10mL of water.; Other Name: Iver P®; Other: Placebo cream; A placebo cream is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender but lacking the permethrin agent.

Outcome Measures

Primary Outcome Measures :

1. Comparing the occurrence of adverse events between the intervention (ivermectin) and control (permethrin) groups [ Time Frame: 15 days ]
   Pruritus will be assessed through physical examination and via diary cards provided to the parents/carers.

Secondary Outcome Measures :

1. Population pharmacokinetic properties of ivermectin at escalating doses [ Time Frame: 15 days ]
   Time to peak plasma concentration (Tmax; hours)
2. Population pharmacokinetic properties of ivermectin at escalating doses [ Time Frame: 15 days ]
   Peak plasma concentration (Cmax; mg/L)
3. Population pharmacokinetic properties of ivermectin at escalating doses [ Time Frame: 15 days ]
   Area under the plasma drug concentration-time curve (AUC0-24; mg×h×L-1)
4. Efficacy of oral ivermectin [ Time Frame: 15 days ]
   Comparing the reduction of dermatological manifestations by "performing physical examination to quantify the number and size of scabies lesions on days 0, 7 and 14" in the oral intervention (oral ivermectin) and control (permethrin cream) groups.

Other Outcome Measures:

1. Pharmacogenomics of ivermectin [ Time Frame: day 0 ]
   Whole genome sequencing will be used to determine associations between pharmacogenetic variants with pharmacokinetic or pharmacodynamic parameters.

Eligibility Criteria

• Ages Eligible for Study: 2 Months to 5 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female child weighing 5 to <15 kilograms
• ≥2 months old
• Scabies infestation
• Available to attend all study visits
• Parents/guardians/carers able to provide consent

Exclusion Criteria:

The participant may not enter the trial if ANY of the following apply:

• A history of renal or hepatic impairment.
• Any other significant disease or disorder (e.g. moderate or severe malnutrition) which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
• Participants who have participated in another research trial involving an investigational product in the past 12 weeks.
• Children with Crusted/Norwegian scabies or severe secondary bacterial infections (e.g. sepsis)
• Children who have taken ivermectin or topical permethrin cream within the last month
• Children with known allergies to ivermectin or topical permethrin cream or excipients
• Loa loa infection risk, assessed based on travel history to endemic areas
• Use of prescription (especially CYP3A4 inhibitors or inducers) or non-prescription drugs (except paracetamol at doses of up to 90 milligrams/kg/day), including vitamins (especially vitamin C), herbal and dietary supplements (including St. John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 times the drug half-life (whichever is longer) prior to the first dose of study medication until the completion of the follow-up procedure, unless in the opinion of investigator, the medication will not interfere with the study procedures or compromise patient safety; the investigator will take advice from the manufacturer representative as necessary.
• The investigator, health care provider or study staff feel that the patient is not suitable for study participation due to chronic illness, suspected underlying illness, or concerns that the patient will adhere to follow-up schedule.
• Not previously enrolled into this study

Contacts and Locations

Contacts

Contact: Lorenz von Seidlein, Ass.Prof.; +66-(0)2-3549170; Lorenz@tropmedres.ac

Contact: Kevin Kobylinski, phD; +66-(0)927298013; kobylinskikevin@gmail.com

Sponsors and Collaborators

University of Oxford

Chittagong Medical College

Fundação Alfredo da Matta (FUAM)

Kenya Medical Research Institute

Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD)

Medical Research Center Unit The Gambia (MRCG)

Investigators

• Principal Investigator: Lorenz von Seidlein, Ass.Prof.; Mahidol Oxford Tropical Medicine Research Unit

More Information

• Responsible Party: University of Oxford
• ClinicalTrials.gov Identifier: NCT04332068
• Other Study ID Numbers: PAR20001
• First Posted: April 2, 2020
• Last Update Posted: June 22, 2022
• Last Verified: June 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Data collected for this study will be under the custodianship of MORU. With participant's consent, data from this study may be shared in a de-identified form with other groups or researchers in accordance with the MORU Data Sharing Policy.
• Time Frame: After completion of trial activities and reporting
• Access Criteria: MORU Data Sharing Policy. (http://www.tropmedres.ac/data-sharing-policy)

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Oxford:

Scabies; Ivermectin; permethrin

Additional relevant MeSH terms:

Scabies; Mite Infestations; Ectoparasitic Infestations; Skin Diseases, Parasitic; Parasitic Diseases; Infections; Skin Diseases, Infectious; Skin Diseases; Ivermectin; Permethrin; Antiparasitic Agents; Anti-Infective Agents; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action